Oncology trials are complex. New technologies creating cutting-edge immunotherapy treatments are creating more complexity. In addition to the medical and scientific issues, enrollment can be a challenge: although cancer is the second-leading cause of death in the United States, fewer than 3% of cancer patients currently enroll in clinical trials for new treatments.
With the progress of the Human Genome Project in recent years, there is an entirely new generation of cancer drugs that offer therapies targeted to the genomics of an individual patient and an individual cancer.
Born as an oncology CRO in 2003, Medelis has the deep oncology expertise available for all aspects of your study.
Relationships are important to us. Reach out to learn more about how our approach, experience, investigator relationships, bid transparency and flexibility deliver success for our clients.